Covariate | Category | CIN1+ | CIN2+ | ||||||
---|---|---|---|---|---|---|---|---|---|
No. of women (N = 982) | No. of women with CIN1+ (N = 50) | HR (95% CI) | p-value | No. of women (N = 982) | No. of women with CIN2+ (N = 29) | HR (95% CI) | p-value | ||
Region | Europe | 644 | 35 | 1 | 644 | 21 | 1 | ||
Asia Pacific | 168 | 6 | 2.99 (1.03-8.70) | 0.0441 | 168 | 3 | 0.76 (0.20-2.93) | 0.6942 | |
Latin America | 76 | 3 | 1.18 (0.34-4.05) | 0.7932 | 76 | 1 | 0.57 (0.07-4.37) | 0.5869 | |
North America | 94 | 6 | 1.93 (0.80-4.68) | 0.1439 | 94 | 4 | 1.73 (0.58-5.18) | 0.3238 | |
0.1480 | 0.6452 | ||||||||
Age at first sexual intercourse | ≥18 years | 801 | 41 | 1 | 801 | 26 | 1 | ||
15-17 years | 181 | 9 | 0.46 (0.21-1.02) | 0.0545 | 181 | 3 | 0.18 (0.05-0.64) | 0.0086 | |
0.0545 | 0.0086 | ||||||||
Number of lifetime sexual partners1 | 1 | 800 | 9 | 1 | 800 | 5 | 1 | ||
2-3 | 537 | 15 | 1.73 (0.72-4.15) | 0.2213 | 537 | 10 | 1.93 (0.63-5.92) | 0.2529 | |
≥4 | 245 | 26 | 5.60 (2.28-13.77) | 0.0002 | 248 | 14 | 4.02 (1.24-13.05) | 0.0203 | |
0.0001 | 0.0504 | ||||||||
Cumulative duration of hormone use for contraception or other indication1 | No use | 804 | 3 | 1 | Not included | ||||
1-12 months | 786 | 13 | 3.61 (0.94-13.86) | 0.0614 | |||||
13-48 months | 707 | 32 | 3.84 (1.00-14.77) | 0.0502 | |||||
>48 months | 102 | 2 | 6.09 (0.89-41.63) | 0.0653 | |||||
0.2157 | |||||||||
Tobacco exposure (number of pack-years)1 | <0.5 | 862 | 36 | 1 | Not included | ||||
≥0.5 | 177 | 14 | 1.44 (0.76-2.74) | 0.2622 | |||||
0.2622 | |||||||||
Previous cervical HPV infection1 | No | 974 | 2 | 1 | 975 | 1 | 1 | ||
Yes | 431 | 48 | 35.70 (8.47-150.50) | <0.0001 | 432 | 28 | 42.30 (5.61-318.63) | 0.0003 | |
<0.0001 | 0.0003 |